XTL Biopharmaceuticals Acquires 85% of NeuroNOS in $32.5M Deal to Target Autism Therapeutics Market
核心洞察
XTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS (搜索) Ltd., a biotechnology company developing disease-modifying therapeutics for Autism Spectrum Disorder (搜索) and neuro-oncology.
The acquisition positions XTL as a major player in the autism therapeutics market, addressing a critical unmet need affecting 1 in 31 U.S. children with no FDA-approved disease-modifying therapies currently available.
NeuroNOS (搜索) has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome (搜索) and Glioblastoma (搜索), with its platform targeting nitric oxide dysregulation in the brain rather than just managing symptoms.
XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB) announced a transformative acquisition agreement to purchase 85% of NeuroNOS (搜索) Ltd., a subsidiary of Beyond Air (搜索), Inc. (NASDAQ: XAIR), positioning the company as a major player in the rapidly expanding autism therapeutics market. The deal addresses one of the most urgent and underserved medical needs in global healthcare, targeting the underlying molecular mechanisms driving Autism Spectrum Disorder (搜索) rather than just symptomatic treatments.
Addressing a Critical Healthcare Crisis
Autism Spectrum Disorder (搜索) now affects approximately 1 in 31 children in the United States, representing a dramatic increase that has placed unprecedented strain on healthcare systems, educational institutions, and millions of families worldwide. Despite decades of research, no FDA-approved disease-modifying therapies exist for autism, with current treatments only managing behavioral symptoms without addressing the underlying neurobiological mechanisms of the disorder.
The urgency has reached the highest levels of U.S. policy, with the administration allocating $50 million in new NIH funding for autism research initiatives. This federal recognition signals a fundamental shift in regulatory priorities and resource allocation toward autism research and treatment development.
Nobel Prize-Winning Scientific Leadership
NeuroNOS (搜索) was founded by Professor Haitham Amal, one of the world's leading autism researchers from Hebrew University of Jerusalem and a visiting scientist at Harvard University, with dozens of peer-reviewed publications advancing the understanding of autism pathophysiology. Professor Amal's groundbreaking research on nitric oxide dysregulation in autism established the scientific foundation for NeuroNOS's therapeutic approach.
The company has strengthened its scientific leadership by bringing on board two Nobel Laureates in Chemistry, Professor Dan Shechtman (Technion) and Professor Roger Kornberg (Stanford University). This unprecedented combination of pioneering autism research with Nobel Prize-winning expertise in chemistry creates a powerful foundation for therapeutic innovation.
Validated Technology Platform
NeuroNOS (搜索)'s drug development platform is based on a proprietary family of small molecules engineered to cross the blood-brain barrier and precisely target diseases associated with nitric oxide (NO) abnormalities in the brain. Preclinical studies have demonstrated that the platform addresses core pathological mechanisms rather than merely alleviating symptoms, with validated NO dysregulation observed in both autism patients and brain cancer patients.
The company has secured two FDA Orphan Drug Designations for Phelan-McDermid Syndrome (搜索) (a rare genetic disorder with strong autism correlation) and Glioblastoma (搜索) (one of the most aggressive and lethal forms of brain cancer). These designations provide seven years of market exclusivity upon approval, tax credits for clinical trial costs, expedited regulatory review, and enhanced FDA engagement.
Transaction Structure and Milestones
XTL will acquire 85% of NeuroNOS (搜索) for consideration including 19.9% of XTL's issued share capital, $1 million in cash, and milestone-based contingent payments totaling up to $32.5 million. The transaction remains subject to customary closing conditions, including approval by XTL's shareholders.
The milestone structure includes clinical development payments of up to $5.5 million to Beyond Air (搜索), commencing from the Phase 1 clinical trial through NDA submission to the FDA. Commercial milestone payments of up to $26 million are payable upon achieving product sales targets.
Leadership Perspectives
"We are extremely excited to enter the autism field, which represents one of the most significant unmet medical needs today," said Noam Band, Chief Executive Officer of XTL Biopharmaceuticals. "With an extraordinary scientific team that includes two Nobel Laureates and Professor Haitham Amal from Harvard and Hebrew University, we have assembled the expertise needed to make a real difference."
Steve Lisi, Chairman and CEO of Beyond Air (搜索) Inc., commented: "This transaction represents a pivotal moment for NeuroNOS (搜索), validating the groundbreaking science we've been developing and also providing the potential to create meaningful value for our shareholders by enabling NeuroNOS's pipeline to advance with dedicated focus and funding."
NeuroNOS (搜索) will now serve as XTL's flagship platform for autism and neuro-oncology therapeutics, with both companies committed to advancing the NeuroNOS product for the treatment of autism to market as quickly as possible.